Phase 3 study of survodutide for weight loss in adults with overweight or obesity and type 2 diabetes mellitus

Phase 3, randomised, double-blind trial of survodutide in obesity and type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage change in body weight from baseline to Week 76 and Achievement of body weight reduction >=5% from baseline to Week 76. Started Jan 2024; status: completed.